Jared Kaltwasser

AJMC - The American Journal of Managed Care

MASH Cirrhosis Trials Lack Consistent End Points

By: Jared Kaltwasser

Many MASH cirrhosis trials use histologic endpoints, but a new review finds limited standardization of these outcomes across studies.

AJMC - The American Journal of Managed Care

Study Challenges Prognostic Importance of Genomic Complexity in CLL

By: Jared Kaltwasser

A consensus definition of high genomic complexity in chronic lymphocytic leukemia may be less important than analyzing the contributions of individual biomarkers.

Managed Healthcare Executive

Efimosfermin wins key designations from FDA, EMA

By: Jared Kaltwasser

The investigational drug for late-stage MASH will now get more robust, proactive guidance from U.S. and European regulators.

Managed Healthcare Executive

Overcoming the overconfidence problem

By: Jared Kaltwasser

Large language models are sure-footed at supplying answers, but what happens in medical contexts when that certainty can be a liability?

Managed Healthcare Executive

With Help of Sanofi, Dario Health Builds Scientific Case for Its Diabetes Program

By: Jared Kaltwasser

Dario is using Sanofi's research infrastructure to evaluate its digital health products.

Managed Healthcare Executive

Agentic AI may take humans out of the loop

By: Jared Kaltwasser

As artificial intelligence agents learn to improve autonomously, the humans who must use and regulate such tools find themselves behind the curve.

Managed Healthcare Executive

Pfizer, Sidekick Health Launch Digital Therapeutic Aimed at Atopic Dermatitis Market

By: Jared Kaltwasser

The launch is one of several digital therapeutics partnerships Pfizer has announced in recent months.

Managed Healthcare Executive

In Digital Health Space, Many Companies Sidestep Rigorous Study

By: Jared Kaltwasser

The report highlights the gap between rigorously tested prescription digital therapeutics and products that make health or economic claims without providing supportive evidence.

Managed Healthcare Executive

Digital Therapeutic for Substance Use Disorder Drives Down Care Utilization, Cost

By: Jared Kaltwasser

Patients using the prescription digital therapeutic saw a decrease of $3,591 in healthcare costs in the six months following treatment initiation.

Managed Healthcare Executive

AI could utterly transform healthcare. But reduce its cost? Perhaps not so much.

By: Jared Kaltwasser

Implementation costs, structural pressures and the labor-intensive nature of healthcare mean that artificial intelligence is unlikely to dramatically lower its costs, at least in the short term.